Matthew Ronsheim - 20 Feb 2024 Form 4 Insider Report for Innoviva, Inc. (INVA)

Role: Officer
Signature: /s/ Matthew Ronsheim
Issuer symbol: INVA
Transactions as of: 20 Feb 2024
Net transactions value: -$12,751
Form type: 4
Filing time: 22 Feb 2024, 21:31:05 UTC
Previous filing: 22 Jan 2024
Next filing: 07 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INVA	Common Stock	Tax liability	$12,751	-807	-2.8%	$15.80	28,010	20 Feb 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.

Remarks:

Dr. Ronsheim is President of Innoviva Specialty Therapeutics, Inc. which is a wholly owned subsidiary of Innoviva Specialty Therapeutics Holdings, LLC, which is a wholly owned subsidiary of Innoviva, Inc.